GSK's (GSK) "Buy" Rating Reaffirmed at Citigroup

Gilead Sciences (NASDAQ:GILD) Given New $156.00 Price Target at Citigroup

Gilead Sciences (NASDAQ:GILD – Free Report) had its price objective increased by Citigroup from $140.00 to $156.00 in a report issued on Tuesday, Marketbeat Ratings reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. Several other equities analysts also recently commented on GILD. Mizuho upped their price target on shares of Gilead Sciences from $131.00 to $140.00 and gave the company an “outperform” rating in …

GSK's (GSK) "Buy" Rating Reaffirmed at Citigroup

Citigroup reiterated a "buy" rating and issued a GBX 1,900 price objective on shares of GSK in a research note on Tuesday.